0001127602-23-028964.txt : 20231205 0001127602-23-028964.hdr.sgml : 20231205 20231205192919 ACCESSION NUMBER: 0001127602-23-028964 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Townsend Adam J. CENTRAL INDEX KEY: 0001773588 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 231468145 MAIL ADDRESS: STREET 1: C/O APELLIS PHARMACEUTICALS, INC. STREET 2: 6400 WESTWIND WAY, SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2023-12-01 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001773588 Townsend Adam J. C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Commercial Officer 1 Common Stock 2023-12-01 4 M 0 110000 15.09 A 186407 D Common Stock 2023-12-01 4 S 0 67557 60.5019 D 118850 D Common Stock 2023-12-01 4 S 0 42443 61.3052 D 76407 D Stock Option (Right to Buy) 15.09 2023-12-01 4 M 0 110000 0 D 2028-11-15 Common Stock 110000 172500 D This is a scheduled exercise and sale from an established 10b5-1 plan. This transaction was executed in multiple trades at prices ranging from $60 - $60.995. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $61 - $61.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This includes 412 shares from 4/30/2023 ESPP purchase. This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service. This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service. /s/ David Watson, attorney-in-fact for Adam Townsend 2023-12-05